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Dysregulation of UPR signaling in
neurons is a key mediator of
neurodegeneration. Smith et al. show that
UPR dysregulation in astrocytes impairs
their ability to support synapses;
modulating astrocytic UPR signaling
prevents neuronal loss and increases
survival in prion-diseased mice.
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Recent interest in astrocyte activation states
has raised the fundamental question of how these
cells, normally essential for synapse and neuronal
maintenance, become pathogenic. Here, we
show that activation of the unfolded protein
response (UPR), specifically phosphorylated pro-
tein kinase R-like endoplasmic reticulum (ER) kinase
(PERK-P) signaling—a pathway that is widely dysre-
gulated in neurodegenerative diseases—generates
a distinct reactivity state in astrocytes that alters
the astrocytic secretome, leading to loss of synap-
togenic function in vitro. Further, we establish that
the same PERK-P-dependent astrocyte reactivity
state is harmful to neurons in vivo in mice with
prion neurodegeneration. Critically, targeting this
signaling exclusively in astrocytes during prion dis-
ease is alone sufficient to prevent neuronal loss and
significantly prolongs survival. Thus, the astrocyte
reactivity state resulting from UPR over-activation
is a distinct pathogenicmechanism that can by itself
be effectively targeted for neuroprotection.
INTRODUCTION
The buildup of misfolded proteins, characteristic of many neuro-
degenerative diseases, is a cellular stress that results in activa-
tion of the unfolded protein response (UPR), a signaling cascade
that aims to restore protein homeostasis (Ron andWalter, 2007).
One branch of the UPR, mediated by phosphorylation of protein
kinase R-like ER kinase (PERK), leads to the transient shutdown
of protein synthesis through phosphorylation of the a subunit of
eukaryotic initiation factor 2 (eIF2a) (Figure 1A). In several mouse
models of neurodegeneration, chronic PERK-eIF2a-P signaling
results in the sustained reduction in global protein synthesisNeuron 105, 855–866,
This is an open access article undrates, leading to synaptic failure and neuronal loss (Moreno
et al., 2012; Radford et al., 2015). Restoration of translation rates
in neurons through genetic or pharmacological modulation of
PERK-eIF2a-P signaling restores memory and synapse function
(Costa-Mattioli et al., 2007; Ma et al., 2013; Sidrauski et al., 2013)
and is profoundly neuroprotective in these models (Celardo
et al., 2016; Grande et al., 2018; Halliday et al., 2015, 2017;
Kim et al., 2014; Mercado et al., 2018; Moreno et al., 2012,
2013; Radford et al., 2015). The pathway has become an area
of intense interest for the treatment of human neurodegenerative
disorders, where increased levels of PERK-P and eIF2a-P occur
in association with misfolded protein accumulation in
Alzheimer’s and Parkinson’s diseases and related disorders
(Hoozemans et al., 2005, 2007, 2009; Smith and Mallucci,
2016; Stutzbach et al., 2013).
Although the neuronal, cell-autonomous effects of dysregu-
lated PERK signaling in neurodegeneration are relatively well
understood, the role of astrocytic UPR activation in disease is
unknown. Astrocytes are key modulators of synaptic structure
and function (Allen et al., 2012; Christopherson et al., 2005;
Chung et al., 2013; Kucukdereli et al., 2011), and their activation
to a ‘‘reactive’’ state is a common feature of neurodegenerative
disorders. Recent observations describe ‘‘neurotoxic’’ and
‘‘neuroprotective’’ reactivity states (Liddelow et al., 2017; Zama-
nian et al., 2012). However, the mechanisms driving astrocyte
reactivity during disease and how this impacts on function and
pathogenesis remain unclear. In this study, we show that chronic
PERK-eIF2a signaling in astrocytes drives a distinct pathogenic
reactivity state both in vitro and in vivo. This state, which we term
‘‘UPR’’ reactive, is characterized by an astrocytic secretome
devoid of synaptogenic properties. It is reversed by PERK inhibi-
tion, which restores synaptogenesis in vitro. Critically, in vivo,
modulation of astrocytic PERK-eIF2a signaling inmice with prion
disease is profoundly neuroprotective, abrogating clinical signs
and prolonging survival, despite ongoing neuronal PERK activa-
tion. The pathogenic role of PERK over-activation therefore has a
significant, non-cell-autonomous component, generating a
distinct reactivity state in astrocytes principally through loss of
synaptotrophic function; this provides multiple new targets forMarch 4, 2020 ª 2019 The Authors. Published by Elsevier Inc. 855
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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restoring synapses and neuroprotection in neurodegenerative
diseases with PERK pathway dysregulation.
RESULTS
Chronic PERK Branch Activation Drives a Distinct UPR-
Reactivity Profile in Primary Cultured Astrocytes
We first confirmed PERK-eIF2a signaling (Figure 1A) in astro-
cytes in vitro and characterized its temporal profile. Primary as-
trocytes, cultured from wild-type mice, were treated with the ER
stressors thapsigargin (Tg) or tunicamycin (Tm) for 2, 6, or 24 h.
PERK activation occurred following 2 h of Tg treatment, with
significantly increased levels of phosphorylated PERK (PERK-
P) and phosphorylated eIF2a (eIF2a-P) at this time point (Fig-
ure 1B), consistent with previous reports (Guthrie et al., 2016;
Sprenkle et al., 2019). This corresponded with an 88% reduction
in global protein synthesis rates at 2 h as a result of rising eIF2a-P
levels (Figure 1C). Elevated levels of the downstream markers of
eIF2a-P signaling, ATF4 and GADD34, were found after 6 and
24 h of Tg treatment, respectively (Figure 1B). Tm, which acti-
vates the UPR through a different mechanism to Tg, drove a
similar temporal pattern of PERK-eIF2a signaling (Figures
S1B–S1E). Thus, primary cultured astrocytes exhibit a typical
PERK-pathway response to ER stressors.
Next, we asked whether PERK signaling affects astrocyte
reactivity in vitro. We assessed the expression levels of a selec-
tion of astrocyte reactivity markers, including ‘‘pan,’’ ‘‘A1,’’ and
‘‘A2’’ markers (Liddelow et al., 2017; Zamanian et al., 2012),
following Tg treatment. The A1 reactivity state, described in
response to a peripheral inflammatory stimulus, is proposed to
be neurotoxic in vitro, whereas the A2 reactivity state, described
in response to ischemia, is proposed to be neuroprotective (Lid-
delow et al., 2017; Zamanian et al., 2012). By 24 h of Tg treat-
ment, the pan-reactive markers Cxcl10, Lcn2, and Vim and the
A1 marker C3 were significantly elevated, with 107-fold,
17-fold, 1.8-fold, and 8-fold increases in mRNA levels, respec-
tively (Figure 1E). In contrast, Ggta1 and Serping1 (also
A1 markers) were significantly reduced, as were Cd109, Emp1
(A2 markers), and the pan-reactive marker, Serpina3n, with
47%, 81%, 90%, 60%, and 52% reductions in transcript levels,
respectively (Figure 1E). Tm treatment induced a similar reac-
tivity profile at 24 h (Figure S1H). Only Emp1 and S100a10 tran-
script levels differed in the profiles generated by the two ER
stressors. Critically, the small molecule GSK2606414, a potent
inhibitor of PERK kinase signaling (Axten et al., 2012), prevented
the Tg-induced rise in eIF2a-P, ATF4, and GADD34 (Figures 1G
and 1H) and, in parallel, significantly reduced the changes to theFigure 1. PERK-eIF2a Signaling Induces a Reactive Phenotype in Prim
(A) Schematic of the PERK branch of the UPR, including the sites of action of th
(B) Western blots showing PERK-eIF2a signaling in primary astrocytes treated w
(C) Primary astrocytes show reduced protein synthesis rates in the presence of T
(D) Quantification of western blots.
(E) qPCR analysis of astrocyte reactivity markers revealed an altered profile on T
(F) Astrocyte reactivity markers that characterize the UPR-reactive profile.
(G) PERK-eIF2a signaling is significantly reduced in primary astrocytes cultured
(H) Western blots quantified.
(I) GSK2606414 significantly blunts the reactivity profile of Tg-stressed astrocytes
ANOVA. n = 3 biological replicates.reactivity profile when co-administered with Tg (Figure 1I) or Tm
(Figure S1H), blunting the increase in Cxcl10, Lcn2, and Vim.
Trazodone, a drug that acts downstream of eIF2a-P to reverse
PERK-eIF2a-P signaling (Halliday et al., 2017), also reduced
the elevated expression of Cxcl10, Lcn2, and Vim, as well as
C3, on Tg treatment (Figure S1I). To exclude any off-target ef-
fects of GSK2606414 (Mahameed et al., 2019; Rojas-Rivera
et al., 2017), we genetically modulated PERK-eIF2a signaling us-
ing small interfering RNA (siRNA) targeting PERK expression. A
73% knockdown of PERK expression significantly reduced the
levels of eIF2a-P on Tg treatment and, crucially, lowered C3,
Cxcl10, Lcn2, and Vim, with 61%, 51%, 82%, and 60% reduc-
tions in transcript levels, respectively (Figure S2). Thus, PERK
signaling is the primary mediator of a distinct astrocytic reactivity
profile in vitro (Figure 1F). We term these astrocytes UPR
reactive.
UPR-Reactive Astrocytes Fail to Support Synapses
In Vitro due to an Altered Secretome
We next tested for functional effects of the PERK-mediated
changes to the astrocyte reactivity state. Astrocytes and astro-
cyte-conditioned media (ACM) have marked trophic effects on
synaptogenesis in primary neuronal cultures (Allen et al., 2012;
Christopherson et al., 2005; Ullian et al., 2001). We therefore as-
sessed the synaptogenic properties of conditioned media from
UPR-reactive astrocytes (Figure 2A). ACM from vehicle-treated
astrocytes significantly increased the synaptic density of primary
hippocampal neurons by 1.65-fold (Figures 2B and 2C), consis-
tent with previous reports (Allen et al., 2012). In contrast, ACM
from Tg-treated astrocytes had no effect on synapse number
(Figures 2B and 2C). PERK inhibition restored the synaptogenic
properties of the ACM, with ACM derived from GSK2606414-
treated Tg-stressed astrocytes significantly increasing synapse
number by 1.47-fold (Figures 2B and 2C). Thus, PERK activation
reduces the synaptogenic function of astrocytes as a result of
the altered UPR-reactivity state.
To better understand the mechanisms underlying the loss of
astrocytic synaptotrophism upon chronic PERK activation, we
compared the secretome of vehicle and Tg-treated astrocytes
using unbiased liquid chromatography/mass spectrometry (LC/
MS) analysis. Conditioned media from vehicle-treated
astrocytes contained an array of proteins essential for synapse
maintenance; constituents of the extracellular matrix, such
as collagen, fibronectin, and glypican-4, a key synaptogenic
factor (Allen et al., 2012), were particularly abundant (Figure 3A;
see Table S1 for full list). The abundance of proteins in the secre-
tome was markedly altered by Tg treatment, with 34 out of theary Cultured Astrocytes
e PERK branch inhibitors, GSK2606414 and trazodone.
ith 300 nM thapsigargin (Tg) for 2, 6, or 24 h.
g, as measured by the incorporation of puromycin into nascent proteins.
g treatment.
in the presence of Tg and 5 mM GSK2606414.
. All bar graphs showmean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; one-way
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Figure 2. UPR-Reactive Astrocytes Fail to Promote Synaptogenesis In Vitro
(A) Schematic illustrating the generation of astrocyte-conditioned media (ACM). Primary astrocytes were treated with vehicle, 300 nM Tg, or 300 nM Tg and 5 mM
GSK2606414. Astrocytes were washed 24 h post-treatment and incubated with fresh neuron media for a further 24 h. Conditioned media were transferred to
primary hippocampal neurons at 18 days in vitro (DIV).
(B) Representative images of primary hippocampal neurons grown without ACM or with vehicle, Tg, or Tg and GSK2606414 ACM. Neurons were immunostained
with the pre-synaptic marker, synaptophysin (magenta) and the post-synaptic marker, PSD-95 (green). Arrows highlight co-localized synaptophysin and PSD-95
puncta. Scale bars, (a) 25 mm; (b–d) 10 mm.
(C) Relative number of synapses normalized to the no ACM condition. Tg ACM failed to promote synaptogenesis, whereas Tg and GSK2606414 ACM retained its
synaptogenic properties. 10 neurons were counted per condition, per biological replicate (n = 3). Bar graph shows mean normalized synapse number ± SEM.
**p < 0.01; ***p < 0.001; n.s., non-significant; one-way ANOVA.127 proteins detected showing at least a 1.3-fold reduction in
spectral counts compared to the secretome of vehicle-treated
astrocytes (Figures 3A and 3B). KEGG (Kyoto Encyclopedia of
Gene and Genomes) and Gene Ontology analysis revealed that
extracellular matrix and cell adhesion pathways were most
significantly affected by Tg treatment (p = 6.9 3 107 and
4.6 3 105, respectively; Figure 3C). Downregulation of these858 Neuron 105, 855–866, March 4, 2020pathways generally, and of the levels of collagen, fibronectin,
and glypican-4, specifically, likely explains the loss of synapto-
trophic support from UPR-reactive astrocytes. Interestingly,
41/127 (32%) proteins showed a 1.3-fold or greater increase in
spectral counts on Tg treatment (Figure 3B; Table S1). These
proteins were largely chaperones involved in protein folding
and processing in the ER, consistent with UPR activation, and
Figure 3. UPR-Reactive Astrocytes Have an Altered Secretome
The proteome of conditioned media from vehicle-, Tg-, or Tg and GSK2606414-treated astrocytes was analyzed by LC/MS.
(A) Heatmap showing normalized spectral counts of the 25 most abundant proteins detected in the conditioned media of vehicle-treated astrocytes. 10 of the 25
proteins showed reduced spectral counts on Tg treatment. These changes were largely reversed by PERK inhibition.
(B) Pie chart showing the percentage of proteins that exhibited an increase, decrease, or no change in spectral counts on Tg treatment.
(C) Bubble plots showing KEGG and GO functional analysis of the proteins that displayed reduced spectral counts on Tg treatment, as determined using DAVID.
Terms relating to the extracellular matrix and cell adhesion were significantly enriched upon PERK activation (p < 0.0001). Size of bubble represents protein count.
LC/MS was performed on conditioned media from 3 biological replicates.included BiP and the neurotrophic factor, MANF (Figures 3B and
S3; Table S1). 52/127 (41%) proteins showed no change in abun-
dance on Tg treatment (Figure 3B; Table S1). Thus, it is likely that
changes to the secretome induced by Tg treatment do not solely
reflect the reduction in global protein synthesis rates that accom-
pany PERK activation (Figure 1C) but likely reflect changes in the
astrocytic translatome under these conditions. PERK inhibition
largely reversed the changes to protein abundance (Figure 3A;
Table S1). The UPR-reactivity state resulting from chronicPERK branch activation therefore alters the secretome of pri-
mary astrocytes, to the detriment of synaptic trophism.
Astrocytic PERK-eIF2a Signaling Drives a UPR-
Reactivity State In Vivo that Is Reversed by Genetic
Modulation of the Pathway
Given the effect of PERK signaling on astrocyte reactivity in vitro
(Figures 1E and S1H), we next examined whether this also oc-
curs in vivo. We used the tg37+/ mouse model of prion disease,Neuron 105, 855–866, March 4, 2020 859
which has been extensively characterized with respect to PERK-
eIF2a signaling and its modulation, particularly in neurons
(Halliday et al., 2015, 2017; Moreno et al., 2012, 2013). Tg37+/
mice express around 3-fold wild-type levels of prion protein
(PrP) and succumb to RML (Rocky Mountain Laboratory) prion
infection 12 weeks post-inoculation (w.p.i.) (Mallucci et al.,
2002, 2003, 2007). Rising levels of misfolded PrP result in high
PERK-P and eIF2a-P and reduced translation rates in the hippo-
campus from 9 w.p.i., followed by the onset of neuronal loss at
10 w.p.i., with the emergence of overt clinical signs and wide-
spread neurodegeneration by 12 w.p.i. (Moreno et al., 2012).
The mice show prominent astrocytosis from 8 w.p.i., with
increased GFAP staining over the course of the disease (Fig-
ure S4A), consistent with previous reports (Mallucci et al.,
2002, 2003). PERK-P staining was detected in astrocytes and
neurons in the CA1 region of prion-infected mice at 10 w.p.i.
(Figure S4B).
We examined hippocampal homogenates of prion-diseased
mice at 10 w.p.i., when PERK signaling is known to be activated
(Moreno et al., 2012) and reactive astrocytosis is established
(Figure S4A). We tested for expression of UPR-reactivitymarkers
defined in vitro (Figures 1E and 1F) and found a pattern of mRNA
transcript expression very similar to that seen in Tg- and Tm-
stressed astrocytes (Figures 1E, 1F, and S1H). Thus, mRNA
levels of C3, Cxcl10, Lcn2, and Vim rose significantly from
9 w.p.i. (Figures 4A and S5A), in parallel with increased PERK-
eIF2a signaling (Figure S5C), and remained elevated through to
the terminal stages of the disease (Figures 4A and S5A). mRNA
levels of Lcn2, a pan-reactive marker, increased more than
250-fold in terminal prion-diseased mice compared to control
tg37+/ mice (Figure 4A). Transcript levels of Sox9, an astro-
cyte-specific nuclear marker, were unchanged through the dis-
ease course (Figure S5A), consistent with an altered reactivity
state rather than merely reflecting an increase in astrocyte num-
ber. RNA scope (Figure 4B) and immunohistochemistry (Figures
4C and 4D) confirmed the astrocytic origins of C3 and Lcn2 tran-
script and protein, respectively, in prion-diseased mice at 10
w.p.i. The rise in these proteins occurred at 9 w.p.i., in line with
increased PERK-eIF2a signaling (Figures S5B–S5D).
In order to modulate PERK-eIF2a signaling specifically in
astrocytes, we generated lentiviral vectors that overexpress an
active fragment of GADD34 (DhuGADD34), the specific inducible
phosphatase of eIF2a-P, under the astrocytic promoter GFAP
(Figure S6A). LV-GFAP-DhuGADD34-transduced primary astro-
cytes (Figure S6B) resulted in reduced eIF2a-P levels and
increased protein synthesis rates on Tg treatment (Figures S6C
and S6D), confirming both functionality of the virus and efficacy
of GADD34 activity in cultured astrocytes. In vivo, mice were in-
jected with LV-GFAP-DhuGADD34 at 5 w.p.i. to allow for viral
expression as disease progressed. Astrocytic expression of
the viral construct was confirmed through detection of lentivirally
mediated expression of GFP (linked to DhuGADD34) in hippo-
campal sections (Figure S6E). Virally expressed DhuGADD34
caused reduced eIF2a-P levels in prion-infected mice at 10
w.p.i. (Figures S6F and S6G). Critically, LV-GFAP-DhuGADD34
treatment of prion-infectedmice reduced the astrocyte reactivity
profile (Figures 5A, S6H, and S6I), consistent with the effects of
PERK inhibitor treatment in vitro (Figure 1G). Levels of C3,860 Neuron 105, 855–866, March 4, 2020Cxcl10, Lcn2, and Vim were reduced by 53%, 63%, 46%, and
35%, respectively, at 10 w.p.i. following LV-GFAP-DhuGADD34
injection (Figures 5A and S6I). The reduction in C3 and Lcn2
transcript levels in astrocytes of GADD34-treated mice was
confirmed by RNA scope (Figure 5B). C3 and LCN2 protein levels
were also significantly reduced in LV-GFAP-DhuGADD34-
treated mice, consistent with reduced astrocyte activation
(Figures 5C and 5D).
Targeting PERK-eIF2a Signaling in Astrocytes In Vivo Is
Profoundly Neuroprotective
In vitro, inhibiting PERK signaling restored the synaptogenic
properties of Tg-stressed astrocytes (Figures 2B and 2C). We
next asked what were the functional sequelae of modulating
PERK signaling in astrocytes in vivo, in the context of over-acti-
vation of the pathway during prion neurodegeneration. We first
observed that lentivirally mediated astrocyte-specific GADD34
expression in prion-diseased mice resulted in a significant and
sustained improvement in burrowing behavior (Figure 6A), a
motivational task sensitive to hippocampal (notably CA1) integ-
rity that correlates with early synaptic dysfunction in prion dis-
ease (Deacon et al., 2001; Mallucci et al., 2007). Control mice
treated with an ‘‘empty’’ virus showed a steady decline in bur-
rowing from 8 w.p.i. In parallel, astrocytic expression of
GADD34 reduced spongiform degeneration (Figure 6B, h versus
f and g) and largely prevented neurodegeneration in the hippo-
campus (Figure 6B, a–h). Astrocytic GADD34 expression
resulted in marked neuroprotection: LV-GFAP-DhuGADD34-
treated mice showed 67% more pyramidal neurons in the
CA1–CA3 region at 12 w.p.i. than mice treated with LV-GFAP-
empty or no virus (p = 0.0002; Figures 6B, see h compared to f
and g, and 6C). Further, lowering astrocytic PERK signaling
throughGADD34 overexpression not only reduced the activation
state (Figures 5A and S6I) but also significantly decreased astro-
cyte density (Figures 6B, compare l with j and k, and 6D), with a
35% reduction in astrocyte numbers and markedly less acti-
vated morphology in GADD34-treated animals (Figures 5C and
5D, e and f). Finally, lentivirally mediatedmodulation of astrocytic
PERK signaling significantly increased survival in prion-diseased
mice to 87 ± 2 days, compared to 82 ± 2 days inmice treatedwith
empty virus (p = 0.0009; Figure 6E). Although this increase may
appear modest, this extension of lifespan is comparable to
survival data where PERK signaling is similarly modulated in neu-
rons, through lentiviral expression of DhuGADD34 under the
neuron-specific CAMKII promoter, and is the result of focal mod-
ulation only (Figure S6J; Moreno et al., 2012). As with neuronally
targeted PERK modulation, levels of PrP and its misfolded dis-
ease-associated isoform, PrPSc, were unaffected by the inter-
ventions (Figure S6K). These data strongly implicate the role of
astrocytic PERK signaling in neuronal demise during disease,
through the loss of critical synaptotrophic support.
DISCUSSION
The processes leading to neurodegeneration involve several cell
types other than neurons. The role of microglia in these disorders
has been extensively studied, but although astrocyte activation
and reactivity are well documented, the mechanisms underlying
Figure 4. UPR-Reactive Astrocytes Upregulate C3 and LCN2 In Vivo
(A) qPCR analysis of hippocampal C3 and Lcn2 mRNA levels across the prion time course. *p < 0.05; **p < 0.01; ***p < 0.001; n = 3 mice per time point.
(B) RNA scope showing the localization of C3 (magenta) and Lcn2 (white) to GFAP+ astrocytes (green) in the hippocampus of prion-diseased mice at 10 w.p.i.
(C and D) Immunostaining of C3 (C) and LCN2 (D) in the hippocampus of prion-diseased mice at 10 w.p.i. Scale bars, 100 mm.
(E) Prion-diseased mice showed a significant increase in the number of C3+/GFAP+ and LCN2+/GFAP+ astrocytes. Bar graphs show mean ± SEM; ***p < 0.001;
Student’s t test. n = 3 mice.
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the astrocytic response to neurodegeneration are still largely
unresolved. These cells were the focus of our study.
The pathogenic role of dysregulated PERK-eIF2a-P signaling
in neurons has been well characterized across the spectrum of
neurodegenerative disorders (Grande et al., 2018; Halliday
et al., 2015, 2017; Hoozemans et al., 2005, 2007; Kim et al.,
2014; Mercado et al., 2018; Moreno et al., 2012, 2013; Radford
et al., 2015; Stutzbach et al., 2013). PERK-P has been detected
in astrocytes from human tauopathy diseases (Nijholt et al.,
2012), but the pathogenic effect of astrocytic PERK signaling,
if any, in these disorders is unknown. Interestingly, the integrated
stress response (ISR), mediated by eIF2a-P signaling, is dysre-
gulated in astrocytes and oligodendrocytes in a group of neuro-
degenerative disorders known as vanishing whitematter disease
(VWMD). In these diseases, mutations in eIF2B, the key interac-
tor of eIF2a-P, lead to demyelination and white matter loss
(Schiffmann et al., 1994; van der Knaap et al., 1997) through
altered eIF2a-P signaling in these cells. Here, we show that
UPR activation in astrocytes, specifically PERK-eIF2a-P
signaling, generates a distinct reactivity state both in vitro and
in vivo, associated with loss of astrocytic synaptic trophism
and neuroprotective functions. Inhibition of astrocytic PERK
signaling reverses this activation state and restores synapto-
genic properties to cultured astrocytes (Figures 1I, 2B, and
2C). In vivo, it has the dramatic effect of affording extensive, pro-
found neuroprotection with prevention of behavioral deficits and
increased survival in prion-diseased mice (Figures 6A–6E). The
extended lifespan (Figure 6E) seen with focal hippocampal mod-
ulation of astrocytic PERK signaling is consistent with observed
protective effects of lentiviral modulation of GADD34 in neurons
and other neuroprotective genetic modifications in prion-
diseased mice (Moreno et al., 2012; Peretti et al., 2015). This
may result from hippocampal neuroprotection modifying
behavior in treated mice in a way that allows amodest but signif-
icant and consistent increase in survival. Alternatively, it may
reflect an extended time course of prion spread when the hippo-
campus is protected. We found a consistent ‘‘UPR-reactive’’
profile, generated in response to two different ER stressors
in vitro, Tg and Tm (Figures 1E and S1H), and to the in vivo stress
of disease-associated protein misfolding (Figures 4A and S5),
specifically prion protein PrPSc here. In each case, the profile is
reversed by direct inhibition of PERK-P by GSK2606414 (Figures
1H and S1H) or downstream of PERK, by inhibition of eIF2a-P
signaling using trazodone (Figure S1I) or via lentivirally mediated
GADD34 expression in vivo (Figures 5A and S6I). The UPR-reac-
tive profile shares a number of markers with previously
described astrocyte reactivity states. A1 reactivity, which is
dependent on microglial activation, in particular, has been sug-
gested as representing a ‘‘neurotoxic’’ phenotype of astrocyte
activation and has been attributed to contributing to pathogen-Figure 5. Genetic Modulation of Astrocytic PERK-eIF2a Signaling Ame
(A) Prion-inoculated mice were injected with lentivirus at 5 w.p.i., prior to synapse
levels of the UPR-reactivity markers C3 and Lcn2 at 10 w.p.i., as analyzed by qP
(B) RNA scope also revealed a reduction in C3 and Lcn2 upon the expression of
(C and D) Protein levels of C3 (C) and LCN2 (D) were similarly reduced by astrocyt
(E) Bar graphs represent quantification of C3+ and LCN2+ astrocytes treated w
Student’s t test. n = 3 mice.esis in a number of human neurodegenerative disorders. In
fact, although A1 astrocytes are neurotoxic in vitro, the in vivo
evidence for the A1 state in disease is confined to the presence
of elevated C3 expression in post mortem samples from a variety
of neurodegenerative diseases (Liddelow et al., 2017). C3 eleva-
tion forms part of the UPR-reactivity profile, probably because
this is a common feature of pathological astrocyte activation.
However, the role, if any, of C3 in mediating pathogenesis is un-
clear, and our data support loss of synaptotrophic function of as-
trocytes over any direct toxic effect as the central pathological
process here. Indeed, recent work identified a very similar profile
in prion-diseased wild-type mice to the UPR-reactive state we
describe, which the authors termed C3+/PrPSc-reactive (Hart-
mann et al., 2019). Interestingly, the C3+/PrPSc-reactivity profile
was largely unaffected by eliminating microglia-induced astro-
cyte activation, through genetic knockout of tumor necrosis fac-
tor alpha (TNF-a), interleukin-1a (IL-1a), and C1q, confirming its
distinction from the A1 state. Indeed, this state may well respond
instead to UPR inhibition, given its similarity to the UPR reactivity
we describe in a different prion mouse model. Rather than A1,
A2, and ‘‘pan’’ reactivity states, we suggest that there are likely
to be multiple reactivity profiles for astrocytes in different dis-
eases, driving pathogenesis through loss of neuronal tropism,
with or without a degree of direct toxicity.
The importance of the PERK-mediated reactivity state in astro-
cytes is apparent through its mechanistic effects of altering the se-
cretome, seen in primary astrocytes (Figure 3). UPR-activated as-
trocytes display a secretome largely devoid of synaptogenic
properties. As a result, the astrocytic component of synapse devel-
opment in cultured hippocampal neurons is absent (Figure 2B).
Many extracellular matrix components, notably collagen, fibro-
nectin, andfilamin, known for their importance insynapse formation
and maintenance (Ferrer-Ferrer and Dityatev, 2018; Hillen et al.,
2018),are reduced inUPR-reactiveastrocytes (Figure3A).PERK in-
hibition restores this property (Figure 3A). Critically, the secretome
changes represent potential targets for synaptic rescue and neuro-
protection for treatment of neurodegenerative diseases that would
avoid systemic, widespread PERK pathway signaling modulation.
Indeed, restoring synapse levels through synaptogenic pathways
involving the cold-shock proteins RBM3 andRTN3 reverses cogni-
tive deficits and prevents neurodegeneration in mouse models of
Alzheimer’s and prion disease (Bastide et al., 2017; Peretti et al.,
2015) and is a powerful neuroprotective strategy. A more in-depth
analysis of the astrocytic secretome—and proteome—may reveal
further small molecules or peptides with synaptogenic properties
that could be candidates for therapeutic intervention.
In conclusion, dysregulated PERK signaling in astrocytes
generates a reactivity state that drives a marked non-cell-
autonomous mechanism of pathogenesis in prion neurodegener-
ation, likely to be relevant across the spectrum of these disordersliorates the UPR-Reactivity State In Vivo
loss. The astrocytic expression of DhuGADD34 significantly reduced themRNA
CR. **p < 0.01; n = 5 mice per condition.
DhuGADD34.
ic DhuGADD34, as determined by immunohistochemistry. Scale bars, 100 mm.
ith DhuGADD34 or empty virus. Bar graphs show mean ± SEM; ***p < 0.001;
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Figure 6. Targeting Astrocytic PERK-eIF2a Signaling Is Neuroprotective in Prion-Diseased Mice
(A) Prion-infected mice received hippocampal injections of LV-GFAP-empty or LV-GFAP-DhuGADD34 at 5 w.p.i. The overexpression of DhuGADD34 prevented
the decline in burrowing behavior at 9, 10, and 11 w.p.i.
(legend continued on next page)
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in which PERK activation occurs. These include the tauopathies,
including Alzheimer’s disease and many other protein misfolding
disorders. Targeting the astrocytic UPR, remarkably, is as protec-
tive as targeting the neuronal component. The data reveal new
mechanisms by which astrocyte reactivity states contribute to
neurodegeneration and provide novel potential synapse-specific
targets for therapy.STAR+METHODS
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Antibodies
Rabbit anti-PERK-P (T980) Cell Signaling Technology Cat# 3179; RRID: AB_2095853
Rabbit anti-PERK Cell Signaling Technology Cat# 3192; RRID: AB_2095847
Rabbit anti-eIF2a-P (S51) Cell Signaling Technology Cat# 3597; RRID: AB_390740
Mouse anti-eIF2a Cell Signaling Technology Cat# 2103; RRID: AB_836874
Rabbit anti-ATF4 Santa Cruz Biotechnology Cat# sc-390063; RRID: AB_2810998
Rabbit anti-GADD34 Proteintech Cat# 10449-1-AP; RRID: AB_2168724
Mouse anti-puromycin Millipore Cat# MABE343; RRID: AB_2566826
Rabbit anti-b-actin Abcam Cat# ab8227; RRID: AB_2305186
Rabbit anti-synaptophysin Synaptic Systems Cat# 101 002; RRID: AB_887905
Mouse anti-PSD-95 Millipore Cat# MABN68; RRID: AB_10807979
Goat anti-C3 R&D Systems Cat# AF2655; RRID: AB_2066622
Goat anti-LCN2 R&D Systems Cat# AF1857; RRID: AB_355022
Chicken anti-GFAP Abcam Cat# ab4674; RRID: AB_304558
Mouse anti-NeuN Abcam Cat# ab104224; RRID: AB_10711040
Rabbit anti-Iba1 Abcam Cat# ab178846; RRID: AB_2636859
Rabbit anti-PrP D-GEN Cat# ICSM35
Bacterial and Virus Strains
LV-CAMKII-GFP This paper N/A
LV-CAMKII-DhuGADD34 This paper N/A
LV-GFAP-GFP This paper N/A
LV-GFAP-DhuGADD34 This paper N/A
Biological Samples
Mouse brain tissue Strains listed in this table N/A
Chemicals, Peptides, and Recombinant Proteins
Thapsigargin Thermo Fisher Scientific Cat# T7459; CAS: 67526-95-8
Tunicamycin Sigma-Aldrich Cat# T7765; CAS: 11089-65-9
GSK2606414 GlaxoSmithKline N/A
Trazodone Sigma-Aldrich Cat# T6154; CAS: 25332-39-2
TNFa Cell Signaling Cat# 8902
IL-1a Sigma-Aldrich Cat# I3901
C1q Biorad Cat# 2221-5504
Critical Commercial Assays
Ggta1 Taqman assay Thermo Fisher Scientific Cat# Mm01333302_m1
H2-T23 Taqman assay Thermo Fisher Scientific Cat# Mm00439246_g1
Serping1 Taqman assay Thermo Fisher Scientific Cat# Mm00437835_m1
Cd109 Taqman assay Thermo Fisher Scientific Cat# Mm00462151_m1
Emp1 Taqman assay Thermo Fisher Scientific Cat# Mm00515678_m1
S100a10 Taqman assay Thermo Fisher Scientific Cat# Mm00501458_g1
Experimental Models: Cell Lines
Mouse: C57BL/6N primary cortical astrocytes Generated in house N/A
Mouse: C56BL/6N primary hippocampal neurons Generated in house N/A
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Experimental Models: Organisms/Strains
tg37+/ mice Imperial College, London Mallucci et al., 2002
C57BL/6N mice Charles River Strain code: 027
Oligonucleotides
Oligonucleotides for qPCR (see Table S2 for sequences) Sigma Aldrich N/A
esiRNA universal negative control Sigma-Aldrich Cat# SIC001
esiRNA targeting mouse Eif2ak3 Sigma-Aldrich Cat# EMU014751
Recombinant DNA
LV-CAMKII-GFP Vigene Biosciences Custom made
LV-CAMKII-DhuGADD34 Vigene Biosciences Custom made
LV-GFAP-GFP Vigene Biosciences Custom made
LV-GFAP-DhuGADD34 Vigene Biosciences Custom made
Software and Algorithms
Prism GraphPad https://www.graphpad.com
ImageJ National Institute of Health https://imagej.nih.gov/ij/docs/guide/
user-guide.pdf
Fiji Fiji https://fiji.sc
Photoshop CS6 Adobe Inc. https://www.adobe.com/products/
photoshop.html
Illustrator CS6 Adobe Inc. https://www.adobe.com/products/
illustrator.htmlLEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Giovanna
Mallucci (gm522@cam.ac.uk). All unique reagents generated in this study are available from the Lead Contact with a completed Ma-
terials Transfer Agreement.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
Tg37+/mice, on a FVB background, were housed in a temperature-controlled room andweremaintained on a 12:12 light dark cycle,
with access to food and water ad libitum. Both males and females were used in this study. Mice were inoculated with 1% brain
homogenate of Chandler/Rocky Mountain Laboratory (RML) prions or normal brain homogenate (NBH) at 3-4 weeks of age, as pre-
viously described (Moreno et al., 2012). Prion-inoculated mice were monitored daily and were culled upon the appearance of confir-
matory prion signs, which occur around 12 weeks post inoculation. Mice were randomly assigned to experimental groups. All animal
work conformed to UK Home Office regulations and institutional and ARRIVE guidelines.
Primary astrocyte culture
Primary astrocytes were isolated from the cortices of both male and female P1 C57BL6/N pups. Briefly, cortical tissue was extracted
into Hibernate A media (GIBCO); meninges were removed and tissue was minced using a scalpel blade. The minced tissue was then
incubated at 37C for 5 minutes in fresh Hibernate Amedia supplemented with 1 mg/mL DNase (Sigma) and 0.25% Trypsin (GIBCO).
The suspension was triturated then returned to 37C for 5 minutes. Trituration was repeated and the suspension was incubated for a
further 5 minutes. 10 mL of glial media (MEM, 10% horse serum, 0.6% D-glucose and 1% Penicillin/Streptomycin) was added and
trituration was performed. The suspension was strained then centrifuged at 200 x g for 5minutes. The cell pellet was re-suspended in
glial media and seeded into T75 flasks (Corning). Cultures were maintained at 37C, 5% CO2 in glial media containing 1% horse
serum. Upon reaching confluency, astrocytes were seeded into 6 well plates (Greiner) at a density of 100,000 cells per well.
Primary neuron culture
Primary neurons were isolated from the hippocampi of both male and female P1 C57BL6/N pups. Briefly, hippocampi were extracted
into Hibernate A media (GIBCO) and incubated at 37C with papain solution for 20 minutes. Papain solution was removed and trypsine2 Neuron 105, 855–866.e1–e5, March 4, 2020
inhibitor was added for 5minutes.Hippocampiwere thenwashed3 times in pre-warmedplatingmedia (Neurobasal A, B27 supplement,
Glutamax, Horse serum, 1M HEPES pH 7.5) before being triturated 8-10 times. The suspension was strained and 300,000 cells were
seeded onto glass coverslips coated with poly-L-lysine. Media was changed to neuron media (Neurobasal A, B27 supplement, Gluta-
max, Penicillin/Streptomycin) 4 hours post seeding. Primary neurons were maintained at 37C, 5% CO2. A third of the media was
changed for fresh media every 3-4 days.
METHOD DETAILS
Prion infection of mice
All animal work conformed to UK Home Office regulations and institutional and ARRIVE guidelines. Tg37+/ mice (males and
females), aged 3-4 weeks, were inoculated with 1% brain homogenate of Chandler/Rocky Mountain Laboratory (RML) prions or
normal brain homogenate (NBH), as previously described (Moreno et al., 2012). Animals were culled when they developed clinical
signs of prion disease, which occurs around 12 weeks post inoculation.
Lentivirus
Lentiviral plasmids were generated by Vigene Biosciences. The catalytically active fragment of human GADD34 was N-terminally
FLAG tagged and placed downstream of either a CAMKII or GFAP promoter. A T2a sequence linked DhuGADD34 to GFP. Plasmids
were packaged by Vigene Biosciences or in house, through the calcium-phosphate transfection of HEK293T cells. Final titers were
1x108 TU/mL.
Stereotaxic injection
Prion-infectedmice were stereotaxically injectedwith lentivirus at 5 w.p.i. under general anesthesia. 5 mL of virus was injected using a
Hamilton syringe at the following 4 sites relative to bregma: (2.0 mm, +2.0 mm, 2.2 mm), (2.7 mm, +2.0 mm, 2.2 mm),
(2.0 mm, 2.0 mm, 2.2 mm) and (2.7 mm, 2.0 mm, 2.2 mm).
Burrowing assay
Burrowing was performed as previously described (Moreno et al., 2013). Briefly, female mice were individually placed in large plastic
cages containing a Perspex tube filled with food pellets. The weight of pellets remaining in the tube after 2 hours was measured and
the percentage burrowed was calculated.
Immunohistochemistry
For neuronal counts, paraffin-embedded brains were sectioned at 4 mm and were stained with hematoxylin and eosin (H&E) or NeuN
(Millipore) as previously described (Moreno et al., 2013). CA1 pyramidal neuronal counts were determined with three serial sections
from three separate mice. For immunofluorescence, sections were baked at 55C for 2 hours before being submerged in 10x Heat
Mediated Antigen Retrieval Solution pH 6.0 (Abcam) and left overnight at 60C. Slides were then washed and blocked for 1 hour in
10% goat serum, 0.1% Triton X-100, 0.3M glycine. Primary antibodies were incubated overnight at 4C. Following washes, Alexa
Fluors (Invitrogen) were applied for 1 hour at room temperature. Slides were mounted with ProLong Diamond Antifade with DAPI
(Invitrogen). Images were captured on a Leica 4000B microscope.
Fluorescence in situ RNA hybridization
Fluorescence in situRNA hybridization (FISH) on brain cryosections was automated on BONDRX robotic stainer (Leica). After manual
post-fixation, epitope retrieval and dehydration, cryosections were processed for 3-plex FISH using the RNAScope LS Multiplex
Assay (ACD) in combination with immunohistochemistry. Tissues were probed against mRNA transcripts C3 (1:1), Lcn2 (1:50) and
GFAP protein (1:2000). The assay was performed according to the manufacturer’s instructions. In brief, samples were permeabilised
with heat and protease treatment to improve probe penetration and hybridization. For heat treatment, samples were incubated in
BOND ER2 buffer (pH 9.0, Leica) at 95C for 2 minutes. For protease treatment, samples were incubated in ACD protease reagent
at 42C for 10 minutes. Prior to probe hybridization, samples were incubated in hydrogen peroxide for 10 minutes to inactivate
endogenous peroxidases and ACD protease. Samples were then incubated in target z-probemixtures for 2 hours at 42C. Each slide
was flushed three times in order to obtain optimal hybridization to transcripts. Following hybridization, branched DNA amplification
trees were built through sequential incubations in AMP1, AMP2 and AMP3 reagents for 15-30 minutes, each at 42C, with LS Rinse
buffer (Leica) high stringencywashes in-between incubation steps. After amplification, probe channels were detected sequentially by
HRP-TSA labeling. Here, samples were incubated in channel-specific HRP reagents for 15 minutes at 42C, TSA fluorophores for
30 minutes and HRP blocking reagent for 15 minutes at 42C. Probes were labeled using Atto 425-Streptavidin (Sigma, 40709,
1:400). Directly following FISH assay, localization of GFAP protein was performed by BOND RX assisted IHC. Samples were incu-
bated with anti-GFAP antibody in blocking solution for 1 hour (Abcam). To develop the antibody signal, samples were incubated
in donkey anti-goat HRP (Thermo Fisher Scientific) for 1 hour, TSA biotin (PE) for 10 minutes and streptavidin-conjugated Alexa
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Fluorescence in situ RNA hybridization - imaging
High-resolution FISH images of tissue sections were acquired on a spinning disk Operetta CLS (Perkin Elmer) in confocal mode using
a sCMOS camera and a 40X NA 1.1 automated-water dispensing objective. The machine was equipped with custom-made narrow
band filters to allow hex-plex imaging. The field-of-viewwas 3203 320 mmand voxel size 0.33 0.33 1 mm. Each field was imaged as
a z stack consisting of 20 to 30 planes with a 1 mm step size. Z-heights of tissue sections were manually determined by imaging DAPI
on sample fields prior to tissue-wide scans. Each z-planewas imaged across 6 channels with exposure times between 60 and 120ms
at 80%LED power. The background correction was applied uniformly across samples, according to control tissue probedwith nega-
tive probes and by omitting primary antibody.
Western blotting
Protein samples were isolated from hippocampi or astrocyte cell pellets using RIPA lysis buffer (150 mL NaCl, 50 mM Tris, 0.5%
sodium deoxycholate, 0.1% SDS and 1% Triton X-100) supplemented with Phos-STOP and protease inhibitors (Roche). 15 mg of
protein was resolved by SDS-PAGE then transferred onto nitrocellulose or PVDFmembranes. Membranes were incubated overnight
with primary antibodies. Horseradish peroxidase secondary antibodies were applied for 1 hour at room temperature at a 1:10,000
dilution (Goat anti-mouse, goat anti-rabbit (BioRad), donkey anti-goat (Promega)). Secondary antibodies were detected with the
enhanced chemiluminescence system (ECL, GE Healthcare). b-actin or GAPDH was used as a loading control and quantitative anal-
ysis was performed with ImageJ.
Co-culture with astrocyte conditioned media
Astrocytes were seeded into 6 well plates at a density of 100,000 cells per well. At 90% confluency, media was removed and cells
were washed 3 times with Neurobasal A (GIBCO). Astrocytes were then cultured in neuron media for 24 hours. Vehicle or drug treat-
ments were added for 24 hours. Media was then removed, astrocytes were washed 3 times with Neurobasal A and fresh neuron me-
dia was added. Following 24 hours, astrocyte-conditioned neuron media was collected and centrifuged at 200 x g to remove dead
cells. Astrocyte-conditioned media was transferred to hippocampal neurons at 18 DIV.
Synapse quantification
Neurons were fixed in 4% paraformaldehyde, 4% sucrose for 20 minutes. Coverslips were washed with PBS then incubated with
0.1% Triton X-100 for 5 minutes, followed by 50 mM NH4Cl for 20 minutes. Neurons were then blocked in 10% goat serum for 1
hour at room temperature. Synaptophysin (Synaptic Systems) and PSD-95 (Millipore) antibodies were diluted in blocking solution
and were incubated overnight at 4C. Following washes in PBS, neurons were incubated for 1 hour at room temperature with
anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 568 (Thermo). Coverslips were stained with DAPI prior to mounting. Images
were captured using a Leica confocal microscope at 63x magnification. The number of co-localized puncta was quantified using the
JACoP plugin in ImageJ. Synapse numbers from 10 neurons were counted per condition per biological replicate.
LC/MS analysis of astrocyte-conditioned media
Astrocytes were seeded into 6-well plates at a density of 100,000 cells. At 90% confluency, cells were washed 3 times with Neuro-
basal A (GIBCO), then cultured overnight in serum-free media (Neurobasal A, Glutamax and Penicillin/Streptomycin). Astrocytes
were treated for 24 hours with vehicle, thapsigargin or both thapsigargin and GSK2606414. Media was collected and centrifuged
for 5 minutes at 4,000 x g to remove any dead cells. Proteins were precipitated using trichloroacetic acid. Precipitates were washed
with acetone, resuspended in SDS-PAGE buffer and separated on a 4%–12% gel. The precipitation procedure was also performed
on serum-free media alone, as an additional control. Proteins were analyzed by LC/MS. A protein was identified if it receivedR 99%
confidence with R 3 unique peptides at 95% confidence in the vehicle- or thapsigargin-treated condition.
Drug treatments
Astrocytes were treated with 300 nM thapsigargin (Thermo) or 3 mg/mL tunicamycin (Sigma) for the indicated time periods.
GSK2606414 and trazodone were added at the same time as the ER stressor, at concentrations of 5 mM and 20 mM, respectively.
The ‘A1-cocktail’ was composed of TNFa (30 ng/mL), C1q (400 ng/mL) and IL-1a (3 ng/mL).
qPCR
Total RNA was isolated with the RNeasy micro kit (QIAGEN), according to manufacturer’s instructions. mRNA was reverse tran-
scribed using the Superscript IV First-Strand Synthesis system (Thermo) and qPCR was performed with Power SYBR Green master
mix (Applied Biosystems). Primers were designed using NCBI primer Basic Local Alignment Search Tool (BLAST) software. Primer
sequences are listed in Table S2. Primer pairs spanned exon-exon junctions, to avoid amplification of genomic DNA. 300 nM forward
primer, 300 nM reverse primer and 1 mL cDNA was used per reaction. qPCR was performed using the QuantStudio 7 Real-Time
System (Applied Biosystems) with the following thermal cycling conditions: 95C for 10 minutes, followed by 40 cycles of 95C
for 15 s, 60C for 1 minute. All primers pairs amplified a single product, as determined using a melt curve. Data was processed using
QuantStudio 6 and 7 Flex software and is expressed as 2-DCT.e4 Neuron 105, 855–866.e1–e5, March 4, 2020
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical details for each experiment, including n numbers and the statistical test performed, can be found in the corresponding
figure legend. Data are presented as mean ± standard error of the mean (SEM). Statistical analysis was performed using Prism
V6 software. Student’s t test was used for datasets with a normal distribution and a single intervention. One-way ANOVA was per-
formed with Tukey’s post hoc test for multiple comparisons. Survival data was analyzed using Mantel-Cox. p < 0.05 was considered
statistically significant.
DATA AND CODE AVAILABILITY
The published article includes all datasets generated during this study.Neuron 105, 855–866.e1–e5, March 4, 2020 e5
